CRP and the disposal of dying cells: Consequences for systemic lupus erythematosus and rheumatoid arthritis

Autoimmunity

Volumn 40, Issue 4, 2007, Pages 295-298

  Vogt, Birgit ^a   Führnrohr, Barbara ^b   Müller, Rüdiger ^b   Sheriff, Ahmed ^a  

^a TheraVision GmbH   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Apoptosis; C reactive protein; Necrosis; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

C REACTIVE PROTEIN; PROTEIN ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

AUTOIMMUNE DISEASE; CELL DEATH; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; INFECTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEPSIS;

EID: 34249810931     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930701358925     Document Type: Review

References (53)

1. Thompson, S., Kelly, CA, Griffiths, ID and Turner, GA (1989) Abnormally-fucosylated serum haptoglobins in patients with inflammatory joint disease. Clin Chim Acta, 184:3, pp. 251-258.
2. Walsh, L., Davies, P. and McConkey, B. (1979) Relationship between erythrocyte sedimentation rate and serum C-reactive protein in rheumatoid arthritis. Ann Rheum Dis, 38:4, pp. 362-363.
3. Mallya, RK, de Beer, FC, Berry, H., Hamilton, ED, Mace, BE and Pepys, MB (1982) Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol, 9:2, pp. 224-228.
4. Walters, MT, Stevenson, FK, Goswami, R., Smith, JL and Cawley, MI (1989) Comparison of serum and synovial fluid concentrations of beta 2-microglobulin and C reactive protein in relation to clinical disease activity and synovial inflammation in rheumatoid arthritis. Ann Rheum Dis, 48:11, pp. 905-911.
5. Mallya, RK, Vergani, D., Tee, DE, Bevis, L., de Beer, FC, Berry, H., Hamilton, ED, Mace, BE and Pepys, MB (1982) Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. Clin Exp Immunol, 48:3, pp. 747-753.
6. Swaak, AJ, van Rooyen, A., Nieuwenhuis, E. and Aarden, LA (1988) Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol, 17:6, pp. 469-474.
7. Rowe, IF, Sheldon, J., Riches, PG and Keat, AC (1987) Comparative studies of serum and synovial fluid C reactive protein concentrations. Ann Rheum Dis, 46:10, pp. 721-726.
8. Bell, SA, Faust, H., Schmid, A. and Meurer, M. (1998) Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol, 113:3, pp. 327-332.
9. Clos, TW Du, Zlock, LT, Hicks, PS and Mold, C. (1994) Decreased autoantibody levels and enhanced survival of (NZB x NZW) F1 mice treated with C-reactive protein. Clin Immunol Immunopathol, 70:1, pp. 22-27.
10. Ogden, CA and Elkon, KB (2005) Single-dose therapy for lupus nephritis: C-reactive protein, nature's own dual scavenger and immunosuppressant. Arthritis Rheum, 52:2, pp. 378-381.
11. Rodriguez, W., Mold, C., Marnell, LL, Hutt, J., Silverman, GJ, Tran, D. and Clos, TW Du (2006) Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum, 54:1, pp. 325-335.
12. Szalai, AJ, Weaver, CT, McCrory, MA, van Ginkel, FW, Reiman, RM, Kearney, JF, Marion, TN and Volanakis, JE (2003) Delayed lupus onset in (NZB x NZW) F1 mice expressing a human C-reactive protein transgene. Arthritis Rheum, 48:6, pp. 1602-1611.
13. Sheriff, A., Gaipl, US, Voll, RE, Kalden, JR and Herrmann, M. (2004) Apoptosis and systemic lupus erythematosus. Rheum Dis Clin North Am, 30:3, pp. 505-527.
14. Sjowall, C., Eriksson, P., Almer, S. and Skogh, T. (2002) Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren's syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun, 19:3, pp. 155-160.
15. Sjowall, C., Bengtsson, AA, Sturfelt, G. and Skogh, T. (2004) Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther, 6:2, pp. R87-R94.
16. Russell, AI, Graham, DS Cunninghame, Shepherd, C., Roberton, CA, Whittaker, J., Meeks, J., Powell, RJ, Isenberg, DA, Walport, MJ and Vyse, TJ (2004) Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet, 13:1, pp. 137-147.
17. Hack, CE, Wolbink, GJ, Schalkwijk, C., Speijer, H., Hermens, WT and Bosch, H van den (1997) A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol Today, 18:3, pp. 111-115.
18. Nijmeijer, R., Willemsen, M., Meijer, CJ, Visser, CA, Verheijen, RH, Gottlieb, RA, Hack, CE and Niessen, HW (2003) Type II secretory phospholipase A2 binds to ischemic flip-flopped cardiomyocytes and subsequently induces cell death. Am J Physiol Heart Circ Physiol, 285:5, pp. H2218-H2224.
19. Kaplan, MH and Volanakis, JE (1974) Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol, 112:6, pp. 2135-2147.
20. Siegel, J., Osmand, AP, Wilson, MF and Gewurz, H. (1975) Interactions of C-reactive protein with the complement system II. C-reactive protein-mediated consumption of complement by poly-lysine polymers and other polycations. J Exp Med, 142:3, pp. 709-721.
21. Volanakis, JE and Narkates, AJ (1983) Binding of human C4 to C-reactive protein-pneumococcal C-polysaccharide complexes during activation of the classical complement pathway. Mol Immunol, 20:11, pp. 1201-1207.
22. Volanakis, JE (1982) Complement-induced solubilization of C-reactive protein-pneumococcal C-polysaccharide precipitates: Evidence for covalent binding of complement proteins to C-reactive protein and to pneumococcal C-polysaccharide. J Immunol, 128:6, pp. 2745-2750.
23. Volanakis, JE (2001) Human C-reactive protein: Expression, structure, and function. Mol Immunol, 38:2, pp. 189-197.
24. Scott, DL (2000) Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford), 39, pp. 24-29.
25. Feldmann, M., Elliott, MJ, Woody, JN and Maini, RN (1997) Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol, 64, pp. 283-350.
26. Buch, MH, Seto, Y., Bingham, SJ, Bejarano, V., Bryer, D., White, J. and Emery, P. (2005) C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum, 52:1, pp. 42-48.
27. Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., Koishihara, Y., Ohsugi, Y., Kumaki, K. and Taga, T. (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA, 90:24, pp. 11924-11928.
28. Bernstein, CN, Blanchard, JF, Leslie, W., Wajda, A. and Yu, BN (2000) The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med, 133:10, pp. 795-799.
29. Loftus Jr, EV, Crowson, CS, Sandborn, WJ, Tremaine, WJ, O'Fallon, WM and Melton 3rd, LJ (2002) Long-term fracture risk in patients with Crohn's disease: A population-based study in Olmsted County, 123, pp. 468-475. Gastroenterology, Minnesota
30. Spector, TD, Hall, GM, McCloskey, EV and Kanis, JA (1993) Risk of vertebral fracture in women with rheumatoid arthritis. BMJ, 306:6877, p. 558.
31. Schett, G., Kiechl, S., Weger, S., Mayr, A., Oberhollenzer, F., Lorenzini, R., Redlich, K., Zwerina, J. and Willeit, J. (2006) High-sensitivity C-reactive protein and risk of non-traumatic fractures in the Bruneck Study. Arch Intern Med, 22, pp. 2495-2501.
32. Cai, H., Song, C., Lim, IG, Krilis, SA, Geczy, CL and McNeil, HP (2005) Importance of C-reactive protein in regulating monocyte tissue factor expression in patients with inflammatory rheumatic diseases. J Rheumatol, 32:7, pp. 1224-1231.
33. Gonzalez-Gay, MA, Gonzalez-Juanatey, C., Pineiro, A., Garcia-Porrua, C., Testa, A. and Llorca, J. (2005) High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol, 32:7, pp. 1219-1223.
34. D'Elia, H Forsblad, Larsen, A., Waltbrand, E., Kvist, G., Mellstrom, D., Saxne, T., Ohlsson, C., Nordborg, E. and Carlsten, H. (2003) Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis, 62:7, pp. 617-623.
35. Pepys, MB, Lanham, JG and De Beer, FC (1982) C-reactive protein in SLE. Clin Rheum Dis, 8:1, pp. 91-103.
36. Vigushin, DM, Pepys, MB and Hawkins, PN (1993) Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest, 91:4, pp. 1351-1357.
37. Rosenau, BJ and Schur, PH (2006) Antibodies to C reactive protein. Ann Rheum Dis, 65:5, pp. 674-676.
38. Herrmann, M., Voll, RE, Zoller, OM, Hagenhofer, M., Ponner, BB and Kalden, JR (1998) Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum, 41:7, pp. 1241-1250.
39. Baumann, I., Kolowos, W., Voll, RE, Manger, B., Gaipl, U., Neuhuber, WL, Kirchner, T., Kalden, JR and Herrmann, M. (2002) Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum, 46:1, pp. 191-201.
40. Botto, M., Dell'Agnola, C., Bygrave, AE, Thompson, EM, Cook, HT, Petry, F., Loos, M., Pandolfi, PP and Walport, MJ (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet, 19:1, pp. 56-59.
41. Perniok, A., Wedekind, F., Herrmann, M., Specker, C. and Schneider, M. (1998) High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus, 7:2, pp. 113-118.
42. Herrmann, M., Zoller, OM, Hagenhofer, M., Voll, R. and Kalden, JR (1996) What triggers anti-dsDNA antibodies?. Mol Biol Rep, 23:3, pp. 265-267.
43. Scott, RS, McMahon, EJ, Pop, SM, Reap, EA, Caricchio, R., Cohen, PL, Earp, HS and Matsushima, GK (2001) Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature, 411:6834, pp. 207-211.
44. Taylor, PR, Carugati, A., Fadok, VA, Cook, HT, Andrews, M., Carroll, MC, Savill, JS, Henson, PM, Botto, M. and Walport, MJ (2000) A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med, 192:3, pp. 359-366.
45. Napirei, M., Karsunky, H., Zevnik, B., Stephan, H., Mannherz, HG and Moroy, T. (2000) Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet, 25:2, pp. 177-181.
46. Bickerstaff, MC, Botto, M., Hutchinson, WL, Herbert, J., Tennent, GA, Bybee, A., Mitchell, DA, Cook, HT, Butler, PJ and Walport, MJ (1999) Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med, 5:6, pp. 694-697.
47. Chitrabamrung, S., Rubin, RL and Tan, EM (1981) Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int, 1:2, pp. 55-60.
48. Agnello, V., De Bracco, MM and Kunkel, HG (1972) Hereditary C2 deficiency with some manifestations of systemic lupus erythematosus. J Immunol, 108:3, pp. 837-840.
49. Hauptmann, G., Grosshans, E., Heid, E., Mayer, S. and Basset, A. (1974) Acute lupus erythematosus with total absence of the C4 fraction of complement. Nouv Presse Med, 3:14, pp. 881-882.
50. Hartung, K., Baur, MP, Coldewey, R., Fricke, M., Kalden, JR, Lakomek, HJ, Peter, HH, Schendel, D., Schneider, PM and Seuchter, SA (1992) Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J Clin Invest, 90:4, pp. 1346-1351.
51. Petry, F. (1998) Molecular basis of hereditary C1q deficiency. Immunobiology, 199:2, pp. 286-294.
52. Morgan, BP and Walport, MJ (1991) Complement deficiency and disease. Immunol Today, 12:9, pp. 301-306.
53. Moroni, G., Trendelenburg, M., Papa, N Del, Quaglini, S., Raschi, E., Panzeri, P., Testoni, C., Tincani, A., Banfi, G. and Balestrieri, G. (2001) Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis, 37:3, pp. 490-498.